Media coverage about Syros Pharmaceuticals (NASDAQ:SYRS) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Syros Pharmaceuticals earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.3628522270994 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
SYRS has been the topic of several analyst reports. ValuEngine cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 22nd. Cann restated a “buy” rating and issued a $28.00 target price on shares of Syros Pharmaceuticals in a research report on Monday, August 21st. Zacks Investment Research cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. Cowen and Company restated a “buy” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, August 9th. Finally, JMP Securities upgraded Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 target price on the stock in a research report on Thursday, September 28th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company. Syros Pharmaceuticals presently has an average rating of “Buy” and an average target price of $26.37.
Syros Pharmaceuticals (NASDAQ SYRS) traded up 3.80% during mid-day trading on Thursday, reaching $17.48. The company had a trading volume of 119,572 shares. The company’s 50 day moving average is $15.91 and its 200 day moving average is $15.91. The stock’s market capitalization is $459.02 million. Syros Pharmaceuticals has a 52-week low of $10.22 and a 52-week high of $24.38.
In related news, Director Richard A. Young sold 3,282 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $22.09, for a total value of $72,499.38. Following the completion of the transaction, the director now owns 423,383 shares in the company, valued at approximately $9,352,530.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric R. Olson sold 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $21.85, for a total transaction of $273,125.00. Following the completion of the transaction, the insider now owns 12,500 shares of the company’s stock, valued at approximately $273,125. The disclosure for this sale can be found here. Insiders sold a total of 21,564 shares of company stock worth $476,803 over the last three months. 33.60% of the stock is owned by company insiders.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
What are top analysts saying about Syros Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Syros Pharmaceuticals Inc. and related companies.